Furthermore, we have shown the therapy resistance of the TNBC line MDA-MB-231 over the estrogen- and progesterone receptor-positive line MCF7, although we failed to advance our understanding of differences in sensitivity to chemotherapy among different types of breast cancers. This evidence concerns the gene PGR and breast cancer.